NOT KNOWN FACTUAL STATEMENTS ABOUT HEMGENIX

CADTH recommends that public drug options reimburse Hemgenix with the therapy of hemophilia B if specified disorders are met.Industry experts noted that the amount of individuals expected to receive etranacogene dezaparvovec in the next three years is uncertain and may be greater than estimated through the sponsor. Need to the whole number of indiv